Cirrhosis due to chronic infection with hepatitis C virus remains by far the most common reason for liver transplantation in North America. Currently, parenteral use of street drugs is the most common means of acquiring hepatitis C. Methadone maintenance therapy is an accepted form of treatment for chronic opiate (eg, heroin) addiction and, not surprisingly, a significant proportion of methadone-treated patients have chronic hepatitis C. The feasibility of liver transplant candidacy in hepatitis patients who require methadone maintenance therapy is controversial, and some transplant centers require patients to withdraw from such therapy in order for the transplant process to move forward. Thus stable patients with end-stage cirrhosis who are receiving methadone maintenance are left in a most difficult situation: discontinue methadone and accept the side effects of withdrawal with the risk of recidivism to use of street opiates, an absolute contraindication for transplantation, or continue methadone therapy and risk exclusion from the transplant process. The issue of methadone replacement therapy in end-stage cirrhosis and the posttransplant literature on the subject are explored in this paper.
KreekMJ. Rationale for maintenance pharmacotherapy of opiate dependence. Res Publ Assoc Res Nerv Ment Dis.1992; 70:205–230.
3.
HallWWardJMattickRP. The effectiveness of methadone maintenance treatment 1: Heroin use and crime. In: WardJMattickRPHallW, eds. Methadone Maintenance Treatment and Other Opioid Replacement Therapies.Amsterdam, The Netherlands: Harwood Academic Publishers; 1998:17–57.
4.
WardJMattickRPHallW. How long is long enough? Answers to questions about the duration of methadone maintenance treatment. In: WardJMattickRPHallW, eds. Methadone Maintenance Treatment and Other Opioid Replacement Therapies.Amsterdam, The Netherlands: Harwood Academic Publishers; 1998:305–336.
5.
CaplehornJRMRossMW. Methadone maintenance and the likelihood of risky needle-sharing. Int J Addict.1995;30(6): 685–698.
6.
KwiatkowskiCFBoothRE. Methadone maintenance as HIV risk reduction with street-recruited injecting drug users. J Acquir Immune Defic Syndr.2001;26(5):483–489.
7.
BallJCRossA. The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services, and Outcomes.New York, NY: Spring-Verlag; 1991:181–182.
8.
AlterMJ. Epidemiology of hepatitis C. Hepatology.1997;26 (3):62S–65S.
9.
AlterMJ. Hepatitis C virus infection in the United States. J Hepatol.1999;31(suppl 1):88–91.
10.
McCarthyJJFlynnN. Hepatitis C in methadone maintenance patients: Prevalence and public policy implications. J Addict Dis.2001;20(1):19–31.
11.
GhobrialRMFarmerDGBaquerizoA. Orthotopic liver transplantation for hepatitis C: Outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg.1999;229(6):824–831.
12.
KochMBanysP. Liver transplantation and opioid dependence. JAMA.2001;285(8):1056–1058.
13.
LiangTJRehermannBSeeffLBHoofnagleJH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med.2000;132(4):296–305.
14.
WeinrieeibRMBarnettRLynchKGDe PianoMAtandaAOlthoffKM. A matched comparison study of medical and psychiatric complications and anesthesia and analgesia requirements in methadone-maintained liver transplant recipients. Liver Transplant.2004;10(1):97–106.
15.
PopovaSRehmJFischerB. An overview of illegal opioid use and health services utilization in Canada. Publ Health.2006;120(4):320–328.
16.
GartryCCOviedo-JoekesELlaliberteNSchechterMT. NAOMI: The trials and tribulations of implementing a heroin assisted treatment study in North America. Harm Reduct J.2009;6:2.
17.
SadockBJSadockVASussmanN. Kaplan & Sadock's Pocket Handbook of Psychiatric Drug Treatment.4th ed.Philadelphia, PA: Lippincott Williams & Wilkins; 2006.
18.
FaggianoFVigna-TagliantiFVersinoELemmaP. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev.2003;(3):CD002208.
19.
Van den BrinkWHaasenC. Evidence-based treatment of opioid-dependent patients. Can J Psychiatr.2006;51(10): 635–646.
20.
MattickRPBreenCKimberJDavoliM. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev.2009;(4):CD002209.
KroekerKIBainVGShaw-StiffelTFongTLYoshidaEM. Adult liver transplant survey: Policies towards eligibility criteria in Canada and the United States 2007. Liver Int.2008;28(9):1250–1255.
25.
DiMartiniAFDewMATrzepaczPT. Organ transplantation. Focus.2005;3(2):280–303.
26.
KanchanaTPKaulVManzarbeitiaC. Liver transplantation for patients on methadone maintenance. Liver Transplant.2002;8(9):778–782.
27.
LiuLUSchianoTDLauN. Survival and risk of recidivism in methadone-dependent patients undergoing liver transplantation. Am J Transplant.2003;3(10):1273–1277.
28.
WongKHLeeSSLimWLLowHK. Adherence to methadone is associated with a lower level of HIV-related risk behaviours in drug users. J Subst Abuse Treat.2003; 24(3):233–239.
HancockMMProsserCCRansibrahmanakulK. Liver transplant and hepatitis C in methadone maintenance therapy: A case report. Subst Abuse Treat Prevent Policy.2007;2:5–8.
31.
FerrariACocciaCPRBertoliniASternieriE. Methadone-metabolism, pharmacokinetics, and interactions. Pharmacol Res.2004;50(6):551–559.
32.
LugoRASatterfieldKLKernSE. Pharmacokinetics of methadone. J Pain Palliat Care Pharmacother.2005;19(4):13–24.
NovickDMGelbAMStengerRJ. Hepatitis B serologic studies in narcotic users with chronic liver disease. Am J Gastroenterol.1981;75(20):111–115.
35.
NovickDMKreekMJArnsPALauLLYancovitzSRGelbAM. Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients. Alcohol Clin Exp Res.1985;9(4):349–354.
36.
WangJSDeVaneCL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)- methadone in vitro. Drug Metab Disp.2003;31(6):742–747.
37.
WeschulesDJBainKTRicheimerS. Actual and potential drug interactions associated with methadone. Pain Med.2008;9(3):315–344.
38.
PengPWMTumberPSGourlayD. Review article: Perioperative pain management of patients on methadone therapy. Can J Anaesth.2005;52(5):513–523.
39.
HayJLWhiteJMBochnerF. Hyperalgesia in opioid-managed chronic pain and opioid-dependent patients. J Pain.2009;10(3):316–322.
40.
HinesSTheodorousSWilliamsonAFongDCurryK. Management of acute pain in methadone maintenance therapy in-patients. Drug Alcohol Rev.2008;27(5):519–523.
41.
BrandsBMarshDC. Methadone maintenance treatment: A Canadian perspective. CMAJ.1997;157(4):399–401.
